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Introduction
Unlike other deep cancers, oral squamous cell car-
cinoma (OSCC), which occurs in the oral cavity, is 
more easily monitored, and specimens are easier to 
collect for diagnosis. However, the 5-year mortality 
rate with oral cancer, at about 50%,1 has not sig-
nificantly changed in the past 50 years despite ad-
vances in surgery, radiotherapy, and chemotherapy. 
This may be because most OSCC cases are diagnosed 
at a late stage, and no reliable early diagnostic 
markers are available. In addition, OSCC has a very 
high recurrence rate, and the early identification 
of recurrence or second primary tumors remains a 
challenge.2 OSCC detection is currently based on an 
expert clinical examination and histologic analysis 
of suspicious areas, but the disease may be unde-
tectable in hidden sites, and most oral lesions are 
often neglected by clinical health care providers. 
Therefore, cytologic sampling combined with sen-
sitive and specific biomarkers for molecular detec-
tion may be the most convenient, low invasive and 
low-cost method for an OSCC diagnosis.
Cytologic diagnoses of malignancies originated 
with Papanicolaou and Traut, who introduced new 
methods for collecting and staining cells in gyne-
cologic diagnoses.3 During the 1980s, a brush was 
introduced for a smear biopsy for better cell 
spreading on objective slides, which was more con-
venient than a wooden spatula.4 The cytologic 
observation and description may include the follow-
ing features: enlarged nuclei, variations in nuclear 
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size and shape (pleomorphism), nuclear borders, a 
decreased nuclear to cytoplasmic ratio, increased 
number of nuclei (multinucleation), binucleation, 
keratinization, tadpole forms, and hyperchromatism. 
According to those criteria, a cytologic diagnosis 
can be staged as inadequate, negative, atypical, 
dysplastic, and tumor cell-positive. However, some-
times this may fail using a conventional cytologic 
diagnosis for OSCC because of the oral topology or 
a hidden lesion. In addition, it is difficult to access 
the deeper cell layer.
Adequate cell sample collection is essential for 
histomorphologic evaluations. Unlike other deep 
cancers, OSCC develops in the oral cavity and is 
much easier to monitor, and shed cancer cells in 
the saliva are easier to collect for diagnosis. In ad-
dition, the low invasive brush sampling to observe 
cancerous transformation is also convenient and 
easily applied. Furthermore, compared with other 
common diagnostic methods for cancer such as 
detecting biomarkers in body fluids, a cytologic di-
agnosis is more sensitive. Therefore, a cytologic di-
agnosis for OSCC is a noninvasive, convenient and 
ideal approach for screening high-risk patients with 
OSCC. In fact, application of liquid-based cytology 
on oral smears collected using a cytobrush showed 
a significant improvement in cell distribution and 
smear thickness, leading to easier identification of 
abnormal cells. The combined use of a cytobrush 
and liquid-based cytology that allows evaluation of 
the epithelial structure of oral epithelial carcino-
mas showed improved accuracy of diagnosis with a 
sensitivity of 95.1% and a specificity of 99.0%.5
Genomic and proteomic approaches have facili-
tated the identification of altered gene or protein 
expressions associated with OSCC. However, few 
such approaches have been integrated into clinical 
practice. In this report, we review recently identi-
fied cytologic markers that were histopathologically 
confirmed in patients with OSCC. These biomarkers 
might have higher potential to be developed as 
liquid-based cytologic diagnostic markers for OSCC 
and biomarkers in body fluids, such as the blood, 
urine or saliva, for detecting the recurrence of OSCC 
in deep areas. In addition, the sensitive labeling 
method and photodynamic approaches that might 
improve the accuracy of cytologic diagnosis of OSCC 
are also described. In addition, potential biomark-
ers that were correlated with typical behaviors such 
as betel quid chewing, which causes OSCC in Taiwan, 
are also included. Modern cytologic diagnostic 
methods and potential biomarkers for cytologic di-
agnoses of OSCC are summarized in Tables 1 and 2.
Modern methods of oral cytology for 
OSCC
Cytomorphometry
The OralCDx BrushTest is a computer-assisted method 
for the analysis of cellular samples collected using 
the brush biopsy. Using a neural network-based image 
processing system, this method can analyze digital-
ized microscopic images of collected cells to detect 
oral precancerous and cancerous cells. OralCDx 
was shown to have a sensitivity and specificity of 
> 90%.48,49
DNA image cytometry
DNA cytometry is a method to measure DNA ploidy. 
By comparing Feulgen dye-stained cytologic samples 
with normal epithelial cells, the malignancy of oral 
mucosal cells can be determined. Remmerbach 
et al.50 reported that DNA aneuploidy might detect 
oral cancer 1−15 months prior to histologic confir-
mation in a clinical setting. In addition, it was also 
suggested that DNA aneuploidy could be an early 
marker to confirm the cytologic diagnosis of cancer 
in patients at high risk of dysplasia.50,51 Sudbo 
et al.52 analyzed archival material and reported 
that the nuclear DNA content of oral leukoplakia 
cells can be used to predict the risk of oral epithelial 
Table 1. Modern methods of oral cytology for oral squamous cell carcinoma
Classification Analytic method Markers References
Cytomorphometry Conventional cytologic diagnosis Cell morphology 3, 6, 7
 Computer-assisted image Cell morphology 5, 8 
  analysis (OralCDx)
DNA analysis DNA image cytometry DNA ploidy, DNA methylation 9, 10
Optical diagnosis Autofluorescence Flavin, tryptophan, elastin,  11
   collagen (endogenous fluorophores)
 Photodynamic diagnosis 5-Aminolevulinic acid 12, 13
  Photofrin 14
 Immunophotodiagnosis antibody targeting EGFR 15
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dysplasia up to 5 years before a histologic diagno-
sis is possible. In addition, a current study reported 
that promoter hypermethylation was associated with 
head and neck squamous cell carcinoma.9 Using a 
DNA cytometric method, an increase in sensitivity 
and specificity of the oral brush biopsy to 100% for 
the early diagnosis of oral cancer was reported.53
In oral cancerization, patients with one oral le-
sion may be at increased risk of developing a further 
malignant tumor. But the detection of an early oral 
lesion is difficult owing to the innocuous appear-
ance. The accuracy of diagnosing high-risk oral ne-
oplasia may sometimes be poor. Several modern 
technologies, including the sensitive labeling method 
or photodynamic approach, were developed as an 
adjunctive method to oral cytologic diagnosis.
Optical diagnosis
An optical diagnosis was proven to be a reliable and 
noninvasive technique for detecting fluorescence 
in tissues that arises from a photosensitizer that is 
taken or endogenously occurs.
Autofluorescence
The use of autofluorescence to detect malignant 
lesions emanated from photodynamic therapy, a 
technique for cancer treatment. Autofluorescence 
describes the biologic characteristic of tissues pos-
sessing endogenous fluorophores such as flavin, 
tryptophan, elastin and collagen, which become flu-
orescent when exposed to certain wavelengths of 
light. The presence of disease can change the con-
centrations of these fluorophores as well as the 
light-scattering and absorption properties of the 
tissue, owing to changes in blood concentration, nu-
clear size distribution, collagen content, and epithe-
lial thickness. The tissue is usually illuminated with 
a light source, mostly in the near-ultraviolet to green 
range of the spectrum. In the human oral cavity, 
the first investigation of in vivo autofluorescence 
Table 2. Biomarkers of oral cytology for oral squamous cell carcinoma
Classification Analytic method Markers References
Extracellular matrix proteins Immunochemical stain laminin-5 γ2 chain 16
 Immunochemical stain High-molecule-weight tenascin-C 17
 Immunochemical stain Mini chromosome maintenance 18
Cell surface markers Immunochemical stain Syndecan-1  19
 Proteomics analysis Mac-2-binding protein 20
 Immunochemical stain Epithelial adhesion molecule 21, 22
 Immunochemical stain γ2 chain of laminin-5 (lam-γ2) 23
 Immunochemical stain Urokinase receptor  23, 24
 Immunochemical stain Plasminogen activator inhibitor-1 23
 Immunochemical stain EMMPRIN (CD147) 25, 26
  and proteomic analysis
 Immunochemical stain CD44s and CD44v6 27
 Immunochemical stain CD109 28
 Immunochemical stain B7-H1 29
 Immunochemical stain E-, P- and N-cadherin 30, 31
 Immunochemical stain Endoglin (CD105) 32
 Immunochemical stain P185 (HER-2/neu) 33
 Immunochemical stain CD46, CD55, CD59 34
 Immunochemical stain  Podoplanin, human PA2.26 34−36
   antigen (T1α-2, podoplanin)
 Immunochemical stain LOXL4 34, 37
Cytoplasmic markers LC-MS/MS, Western blotting SERPINB1 38
 RT-PCR PIN1 39
 Immunohistochemistry HIF1α 40−42
 Immunohistochemistry ANXA1 43
 Immunohistochemistry RANK/RANKL 44
Macrophage Immunohistochemistry and CD68 40, 45
  infiltrated cell count
Cancer stem cells Cell sorting CD44, CD133, CD34 46
 Immunohistochemistry  Oct-4, Nanog, CD117, nestin,  47
   CD133, and ABCG2
LC = liquid chromatography; MS/MS = tandem mass spectrometry; RT-PCR = reverse transcriptase-polymerase chain reaction.
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imaging was performed by Harris and Werkhaven54 
and Harris et al.,55 who noted endogenous autoflu-
orescence at around 630 nm in tumors of the oral 
mucosa. However, autofluorescence of normal tissues 
was also observed. The sensitivity of this fluorescence 
detection method was improved by an associated 
porphyrin injection for detection. Porphyrin, which 
may rapidly accumulate in tumors compared with 
that in the surrounding normal tissue, is the most 
commonly used target in autofluorescence-detecting 
oncology. However, porphyrin-based tumor detection 
might only be useful for diagnosing advanced tumors 
because of its high false-positive potential.
Photodynamic diagnosis
Photodynamic diagnosis of an oral carcinoma and 
precursor lesions mainly uses 5-aminolevulinic acid 
(5-ALA), which is a precursor of the fluorescent 
photosensitizer, protoporphyrin IX (PpIX), which 
can be administered systemically or applied topi-
cally to the oral mucosa and facial skin. Excessive 
accumulation of 5-ALA-induced PpIX results in the 
accumulation of intracellular porphyrins, especially 
PpIX, which increases the tissue fluorescence. 
When Sharwani et al.12 used 5-ALA in the form of 
a mouth rinse to test 71 patient with clinical sus-
picion of leukoplakia to identify dysplasia or car-
cinoma in situ, a sensitivity of 83−90% and a 
specificity of 79−89% were obtained. Chang and 
Wilder-Smith14 reported that a photodynamic diag-
nosis, Photofrin, was used topically to detect early 
oral cancer with a sensitivity of 92.45% in a macro-
scopic study and 93.75% in a microscopic study. The 
epidermal growth factor receptor (EGFR) is over-
expressed in oral cancer. Soukos et al.15 used an anti-
EGFR monoclonal antibody coupled to the fluorescent 
dye, N,N-di-carboxypentyl-indodicarbocyanine-5,5-
disulfonic acid, to detect a tumor-associated antigen 
of the EGFR. This method using a specific antibody 
coupled with a fluorescent dye improved the de-
tection accuracy to specificities of 95.65% in the 
macroscopic study and 97.50% in the microscopic 
study. In addition, 5-ALA-induced PpIX accumulation 
might lead to selective killing of macrophages at 
the site of photodynamic treatment in OSCC56 and 
downregulate the invasion.57 Recent studies dem-
onstrated improved sensitivity and specificity, and 
the potential for the immunophotodiagnosis of OSCC.
Molecular analysis using biomarkers for 
a cytologic diagnosis of OSCC
An immunocytochemical analysis of oral brush biop-
sies can recognize atypical cells by detecting altered 
protein expressions by tumor cells. In brush biopsies 
of OSCC, the following immunocytochemical pat-
terns may be observed: (1) staining of cytoplasm, 
(2) banded markings between clumped carcinoma 
cells, and (3) positive hazes surrounding atypical 
cells. The immunocytochemical marking of atypi-
cal cells in brush biopsies makes it easier to locate 
suspicious cells, which facilitates the diagnosis and 
raises the sensitivity of the biopsy. Many proteins 
that were successfully detected by immunochemi-
cal staining and correlated with OSCC were reported 
and described as follows. These proteins may be 
potential biomarkers for a molecular analysis of 
oral cytology of OSCC.
During the malignant transformation of cells, 
the structure or expression level of some proteins 
in the extracellular matrix (ECM) may be altered. 
Transformation of squamous cell carcinomas with 
invasiveness and metastatic potential is associated 
with a poor survival rate. The cell surface mole-
cules involved in cell migration and invasion might 
be potential markers for monitoring malignant phe-
nomena. In addition, there is considerable interest 
in exploiting improved understanding of the biology 
of cancer cells to develop biomarkers capable of dis-
tinguishing malignant and dysplastic cells18. Using 
the minimally invasive brush biopsy, sufficient num-
bers of suspicious oral mucosal cells can be collected 
to search for potential biomarkers using genomic, 
proteomic or immunochemical staining approaches. 
Potential cell surface markers of OSCC were sur-
veyed by clinical histopathologic immunochemical 
staining methods listed in Table 2.
ECM proteins and cell surface markers
Both the laminin-5 γ2 chain and tenascin-C pro-
teins have key functions in the cascade of invasion 
and metastasis of OSCC.58 Their expressions at both 
the messenger RNA and protein levels are signifi-
cantly high.16,17,59 Laminin-5 is a key protein of the 
epithelial adhesion complex that is involved in the 
process of invasion and metastasis. Significantly 
higher expression levels of those ECM molecules 
were demonstrated in cells of oral lesions in OSCC 
using the brush biopsy.60
In contrast to the intact laminin-5 molecule, the 
isolated laminin γ2 chain acts as a potent factor in 
cell migration and invasion. The laminin γ2 chain was 
found to be resynthesized in the squamous cell 
carcinoma invasion zone and eventually deposited in 
the stroma of the invasion zone.61 Increased expres-
sion of the laminin γ2 chain was associated with poor 
survival in patients with OSCC.62 The combination of 
conventional cytologic and immunochemical analyses 
using an anti-laminin γ2 chain antibody achieved a 
sensitivity of 93% and a specificity for brush biopsy 
diagnostics of up to 98%.16 Formation of ECM with 
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a high tenascin-C content is a characteristic feature 
of a variety of carcinoma types.17 The tenascin-C 
matrix is synthesized by the carcinoma cells them-
selves, especially by those in the invasion zone and 
in precursor lesions. In inflammatory oral mucosal 
lesions, excessive tenascin-C of the ECM is also seen. 
Unlike normal tenascin-C, it is a high-molecular-
weight variant. By including high-molecular-weight 
tenascin-C detection, the cytologic analysis increased 
the sensitivity and specificity of the conventional 
biopsy diagnosis from 78% to 96% and 95% to 99%.17 
Chuang et al.63 reported that high podoplanin ex-
pression was statistically significantly correlated with 
clinical nodal metastasis.
Cytoplasmic markers
Some cytoplasmic proteins which regulate oncogenic 
mechanisms may be potential targets for early 
tumor detection or tumor recurrence. The expres-
sion of SERPINB1 (serine protease inhibitor, clade B, 
member 1) was significantly higher in oral cancer 
cells with high motility, and the overexpression of 
SERPINB1 in invasive OSCC was clinicopathologically 
confirmed.38 Overexpression of PIN1, a prolyl iso-
merase which regulates phosphorylation of Ser/Thr-
Pro motifs, was associated with progression of 
OSCC.39 Overexpression of hypoxia-inducible fac-
tor-1α (HIF-1α), which reflects the presence of hy-
poxia, was correlated with poor survival and tumor 
progression in patients with OSCC.40−42,64−66 In ad-
dition, messenger RNA expression of annexin A1 
(ANXA1) was found in the peripheral blood of pa-
tients with OSCC.67 A proteomics approach demon-
strated downregulation of ANXA1 in OSCC-derived 
cell lines.68 More interestingly, the evidence of nu-
clear localization of the ANXA1 protein from the cy-
toplasm to nuclei was associated with poor survival 
of patients with OSCC.43 Marked downregulation of 
plasma membranous ANXA1 was correlated with 
the poorly differentiated status of OSCC cells.69,70 
Monitoring of the nuclear translocation of ANXA1 
can be a potential marker for a diagnosis and prog-
nosis of OSCC. The receptor activator of nuclear 
factor-κB (RANK) and its ligand (RANKL), which are 
involved in osteoclastogenesis leading to bony de-
struction, were potentially associated with bony 
invasion in patients with OSCC.44
Marker cells
The presence of typical cells may be correlated with 
tumor progression. The infiltrating macrophage count 
was correlated with the progression of OSCC and is 
a prognostic marker.40,45
Cancer stem cells (CSCs) are tumor cells, which 
have stem features such as self-renewal, a high 
migration capacity, drug resistance, and high pro-
liferation abilities. There is increasing evidence 
that the growth and spread of cancers is driven by 
a small subpopulation of CSCs, which are the only 
cells that are capable of long-term self-renewal 
and generation of a phenotypically diverse tumor 
cell population. Failure of cancer therapies may 
be due to quiescent CSCs that remain vital and re-
tain their full capacity for tumor repopulation.71 In 
addition, the development of new CSC-targeted 
therapy is hindered by the lack of reliable markers 
for identifying CSCs and a poor understanding of 
their behavioral determinates. A cytofluorimetric 
analysis targeting stem antigens may be an efficient 
method to identify and recognize CSCs. CSC-specific 
surface markers such as CD44, CD133 and CD34 have 
been used in CSC isolation.46 Chiou et al.47 found 
that enriched oral cancer stem-like cells highly ex-
pressed stem/progenitor cell markers such as Oct-4, 
Nanog, CD117, nestin, CD133 and ABCG2, and posi-
tive correlations of Oct-4, Nanog and CD133 expres-
sions with the tumor stage were detected.
Biomarkers correlated with 
environmental carcinogens, areca 
(betel) chewing, and smoking in 
patients with OSCC
The prevalence of OSCC in Taiwan as well as in the 
other Asian countries is highly associated with betel 
quid chewing and smoking.72−75 Chewing areca quid 
generates reactive oxygen species that might cause 
oxidative DNA damage to surrounding tissues in 
the oral cavity.76 In addition, the areca nut extract 
can impair actin organization that causes fibroblas-
toid morphologic changes of oral keratinocytes.77 
The genetic susceptibility to such environmental 
carcinogens and the resulting altered molecular 
expressions might be potential markers for a diag-
nosis and prognosis of OSCC.75 Studies in patients 
with OSCC associated with the use of betel nut 
and/or tobacco showed significantly altered expres-
sions of genes and proteins (Table 3) such as the 
fragile histidine triad (FHIT),80 p53,81 loss of nu-
clear retinoic acid receptor-β,88 EGFR, Her-2,82,83 
vascular endothelial growth factor (VEGF),84 high-
molecular-weight microtubule-associated protein 2 
(hmw-MAP2),98 and soluble receptor II for tumor 
necrosis factor-α (sTNF-RII),85 downregulation of 
S100A2,89 increased expressions of matrix metal-
loproteinase (MMP)-178 and MMP-8,79 and increased 
activities of Src family kinases in invasive tumor 
fonts86 and in smoking/betel-using patients associ-
ated with somatic mitochondrial DNA mutations.87 
In addition, chromosomal mutations, the polymor-
phism including CYP1A1 at exon 7 containing the 
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A/G (Ile/Val) genotype,90 longer (GT)n repeat alle-
les in the heme oxygenase (HO)-1 promoter91 and 
nuclear factor-κB promoter,92 deletion of chromo-
somes 4p and 9q associated with poor outcomes of 
betel-using patients with OSCC,93 and aberrant 
copy numbers of cyclin D1 (CCND1) and/or cortactin 
(CTTN) on chromosome 11q13 correlated to areca-
associated OSCC94 were also reported. Combina-
tional polymorphisms of DNA repair genes of XRCC1, 
XRCC2, XRCC3, and XRCC4,95 and the XRCC4 intron 
3 delete genotype96 were highly associated with 
people who have the betel nut chewing habit and 
are susceptible to OSCC; in addition, the polymor-
phism in the promoter of cyclooxygenase-2-1195A/A 
contributed to the development of betel-related 
OSCC.97
Biomarkers for oral cancers in Taiwan
In Taiwan, oral cancer has been one of the top ten 
causes of death from cancer since 1991.99 The prev-
alence showed a 5.3-fold increase for men and a 
twofold increase for women over two decades.100 
In addition, the annual death toll for oral cancer in 
males has rapidly increased.101 As described in the 
previous section, betel quid chewing and smoking 
are the two major risk factors associated with the 
prevalence of OSCC in Taiwan.102−104 The expres-
sion of more than 20 biomarkers in betel quid 
chewing-related OSCCs from Taiwan was studied 
by immunohistochemistry in the past two dec-
ades.21,41,43,105−121 In comparisons of protein expres-
sion levels in specimens of normal oral mucosa, 
oral epithelial hyperplasia and oral epithelial dys-
plasia, the majority of these biomarkers are over-
expressed in OSCC specimens,21,41,43,105−119 with 
very few biomarkers including p27KIP1, metastasis-
associated protein 1 and epithelial cell adhesion 
molecule (Ep-CAM) being downregulated in OSCC 
samples.21,118,119 Overexpression of cyclin D1, p53, 
p21WAF1, cyclin A, survivin, human telomerase reverse 
transcriptase (hTERT), HIF-1α, receptor-binding 
cancer antigen expressed on SiSo cells (RCAS1), 
ANXA1, histone deacetylase 2, and B-cell lymphoma 
10 (BCL10) in OSCC samples were correlated with 
poorer overall survival of OSCC patients.21,41,43,105−120 
Downregulation of p27KIP1 and Ep-CAM in OSCC 
Table 3. Potential biomarkers for a cytologic diagnosis of environmental carcinogen-induced oral squamous cell 
carcinoma
Classification Analytic method Markers References
Extracellular matrix RT-PCR, antibody neutralization and MMP-1 78
 molecule expression  antisense oligodeoxynucleotides to
  reverse cell mobility
 Immunoblot analysis MMP-8 79
Cytoplasmic markers RT-PCR and immunochemistry FHIT 80
 Immunohistochemistry p53 81
 Enzyme immunoassay, ELISA,  EGFR, Her-2 82, 83
  and immunohistochemistry
 Immunohistochemistry VEGF 84
 Immunohistochemistry hmw-MAP2  84
 ELISA sTNF-RII 85
 Immunohistochemistry Src family kinase 86
 Temporal temperature gradient Mitochondrial DNA mutation 87
  gel electrophoresis
Nuclear markers  In situ hybridization Nuclear retinoic acid receptor-β 88
 RT-PCR, Southern blotting,  S100A2 89
  immunochemical stain
Chromosomal mutations Polymorphism CYP1A1 90
 Polymorphism HO-1 91
 Polymorphism Nuclear factor-κB 92
 Genomic hybridization Chromosome 4p and 9q 93
 Q-PCR CCND1 and CTTN 94
 PCR-restriction fragment XRCC1, XRCC2, XRCC3, XRCC4 95, 96
  length polymorphism
 PCR-restriction fragment Cyclooxygenase 2 97
  length polymorphism
RT-PCR = reverse transcriptase-polymerase chain reaction; ELISA = enzyme-linked immunosorbent assay; Q-PCR = quantitative 
polymerase chain reaction; PCR = polymerase chain reaction.
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samples was also associated with poorer overall 
survival of OSCC patients.21,118,119 In addition, over-
expression of cyclin A, hTERT, HIF-1α, RCAS1, his-
tone deacetylase 2, BCL10, ras p21, hepatocyte 
growth factor, c-met, erythropoietin, erythropoie-
tin receptor, p34cdc2, and cellular inhibitor of ap-
optosis protein 1 in OSCC samples was correlated 
with larger tumor sizes, more regional lymph node 
metastasis, and more-advanced clinical stages of 
OSCCs.41,107,109−116,121 Furthermore, downregulation 
of metastasis-associated protein 1 and Ep-CAM was 
also related to larger tumor sizes, more regional 
lymph node metastasis, and more-advanced clini-
cal stages of OSCCs.21,119 Overexpression of cyclin A 
and BCL10 and downregulation of Ep-CAM in OSCC 
samples were associated with the recurrence of 
OSCCs.21,107,121 Moreover, the overexpressions of 
hTERT and ras p21 were correlated with betel quid 
chewing and smoking habits of OSCC patients.109,112
Conclusion
In summary, cytologic observations are convenient 
and can be a noninvasive method for the diagnosis 
and prognosis of OSCC, since shed cancer cells can be 
collected from saliva in the oral cavity. Advanced 
oral cytology associated with a sensitive detection 
method using specific biomarkers as described in 
this review may improve the accuracy of the pre-
liminary clinical inspection of oral cancer and the 
prognosis after treatment. Therefore, cytologic di-
agnostic methods may be valuable for screening 
high-risk cases of OSCC before further histologic 
confirmation. Larger-sized clinical studies are re-
quired to confirm the specificity and sensitivity of 
some of the markers listed in this review. This arti-
cle provides a view of future work to search for 
useful biomarkers and put them into clinical use.
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